/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | ERNAWErnexa Therapeutics |
|---|---|
| Last close | $0.05 |
| Change % | -16.19% |
| Market cap | $81947.0322 |
| P/E | — |
| Revenue | $582000 |
| Rev growth (YoY) | 755.9% |
| Net income | $-14084000 |
| Net margin | -2419.9% |
| EPS (diluted) | $-2.24 |
| Piotroski F-ScoreUNVALIDATED | 4 |
| Altman Z-ScoreUNVALIDATED | -71.35 |
| Beneish M-ScoreUNVALIDATED | — |
| Next earnings | rep. 03-20 |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Green = best in the row among the compared names. Educational only — not investment advice.